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INTRODUCTION
Mycobacterium tuberculosis (TB) is globally the most com-
mon opportunistic infection affecting HIV-1-seropositive
individuals, and it remains the most common cause of death
in patients with AIDS (Pawlowski et al., 2012). Mycobacte-
rium tuberculosis and HIV-1 act in synergy, creating a
global public health problem by accelerating the decline of
immunological functions and leading to subsequent death if
untreated. The mechanisms behind the breakdown of the
immune defence of the co-infected individual are not well
known. It is known that host protective immune response
against this pathogen is mediated by cellular immunity in
which specific cytokines and Th1 cells have a critical role
(Chen and Kolls, 2013). Understanding the mechanisms in-
volved in this response, and in particular the function of the
cytokine network involved in this disease, is of significant
relevance in making advances in the development of effec-
tive control and prevention. An important aspect associated
with the production of cytokines in TB infection is the acti-
vation of macrophages in response to interferon- (IFN-)
signalling, and also promoting the migration of immune
cells to the infection site, which controls disease progres-
sion. The regulation of the innate and the adaptive immune
responses are extensively intertwined and tightly regulated.
Ag-driven immune responses that are modulated by im-
mune complexes (ICs) are known to inhibit IFN--depend-
ent MHC class II expression (Boekhoudt et al., 2015). Past
research has led to the general conclusion that IFN- is
much more than an interferon, in that it has broader effects
on the various arms of the immune system than most any
other lymphokines or cytokines. In review (Young and
Hardy, 1995) discussed the effects of IFN- on the various
cell lineages of the immune system, focusing on the biology
of its actions. IFN- plays various roles in the pathogenesis
of HIV-1/AIDS (Young and Hardy, 1995). In HIV-1 in-
fected individuals, the production of IFN- is detected early
in the acute phase. Results from both in vitro and ex vivo
studies show that IFN- can promote HIV-1 virus replica-
tion and is associated with disease development. On the
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The aim of this research was to investigate the role of IFN- in interaction between IL-10, IL-18,
IL-1b, CD4 cell counts and HIV-1 RNA viral load in the development of HIV-1 in patients
co-infected with Mycobacterium tuberculosis (TB). The study was conducted by Rîga East Clinical
University Hospital with data from the HIV-1 register, in collaboration with the RSU Joint Labora-
tory of Clinical Immunology and Immunogenetics. 200 HIV-1 infected patients and 184 HIV-1 with
TB co-infection patients divided in four groups were included in the study. IFN-, IL-10, IL-18,
IL-1b levels were measured in serum with commercially enzyme-linked immunosorbent assay
(ELISA Vector-Best Corporation, Novosibirsk, Russia). CD4 cell counts were measured by flow
Partec IVD cytometry (USA). HIV-1 RNA quantification was performed using the COBAS
AmpliPrep/COBAS Taqman HIV-1 Test (Germany). All groups were compared with each another.
IFN- production was significantly lower, and IL-10 and CD4 cell counts were significantly higher,
in HIV-1 patients without TB compared with the other groups. The group with HIV-1 and TB had
significantly elevated IL-18 production. HIV patients with primary TB had significantly elevated
IFN- production and HIV-1 RNA viral load and significantly lower IL-10 production.
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other hand, IFN- has been shown to promote cytotoxic T
lymphocyte and NK cell activities against HIV-1 infected
cells, which are important in controlling HIV-1 replication.
Both TB and HIV-1 have profound effects on the immune
system, as they have the ability to disarm the host's immune
responses, through mechanisms that are not fully under-
stood. HIV-1 co-infection is the most powerful known risk
factor for progression of M. tuberculosis infection; it in-
creases the risk of reactivation of latent TB by 20 times
(Selwyn et al., 1989; Getahun et al., 2010). Likewise, TB
has been reported to exacerbate HIV-1 infection (Whalen et
al., 1995; Modjarrad and Vermund, 2010). Various lines of
evidence indicate that inborn errors of immunity, as well as
genetic polymorphisms, have an impact on susceptibility to
TB and HIV-1 (Moller and Hoal, 2010).
The aim of this study was to investigate the role of IFN- in
interaction between IL-10, IL-18, IL-1b, and CD4 cell
counts and HIV-1 RNA viral load in the development of
HIV-1 in patients co-infected with Mycobacterium tubercu-
losis.
MATERIALS AND METHODS
This study was conducted in the Rîga East Clinical Univer-
sity Hospital “Latvian Center of Infectology”, Latvia (LCI)
and Rîga Stradiòð University, Joint Laboratory of Clinical
Immunology and Immunogenetics. Medical documentation
(ambulatory cards) were examined for 600 patients in the
period from 2004 to 2014, and based on criteria for inclu-
sion and exclusion, 384 HIV-1 positive patients with AIDS
stages were included in our study, and 184 of all HIV-1
positive patients were co-infected with TB. All patients
were acquainted with the document “Information for pa-
tients” and signed the “Patient Agreement Statement”. The
184 HIV-1 with TB co-infection patients were separated
into three groups: HIV-1 patients with primary TB (n = 80),
HIV-1 patients with secondary TB (n = 12), and HIV-1 pa-
tients with TB of more than five years duration (HIV-1+
TB) (n = 92). HIV-1 patients without TB were used as a
control group (n = 200). Clinical characteristics of the study
population are shown in Table.1
IFN-, IL-10, IL-18, IL-1b levels were measured in serum
with commercially enzyme-linked immunosorbent assay
(ELISA Vector-best corporation, Novosibirsk, Russia) in
Rîga Stradiòð University, Joint Laboratory of Clinical Im-
munology and Immunogenetics. The measurement ranges
were 0 to 1000 pg/ml for IFN-, 0 to 500 pg/ml for IL-10, 0
to 1000 pg/ml for IL-18, and 0 to 250 pg/ml for IL-1b. Con-
centrations of cytokines were determined using an absorb-
ance microplate reader HiPo (Biosan, Latvia) and micro-
plate data collection and analysis software (Biosan, Latvia).
CD4 cell counts were estimated by flow cytometry
(FastTrack; Becton Dickinson, San Jose, CA, USA). For
HIV-1 RNA quantification, 100 l of plasma was sus-
pended in 900 mkl phosphate buffered saline (PBS), and the
samples were analysed using the COBAS AmpliPrep/
COBAS Taqman HIV-1 Test 2.0 (Roche diagnostics,
GmbH, Mannheim, Germany), in accordance with manufac-
turer's instructions. Determination of CD4 cell counts and
HIV-1 RNA were performed at the LCI Laboratory.
Data are presented as median value. Nonparametric meth-
ods were performed using Microsoft Office Excel 2003 and
DOS Stat Calc software (Anonymous, 2013).
All authors hereby declare that all experiments have been
examined and approved by the appropriate ethics committee
No. 27.09.2012 and have therefore been performed in ac-
cordance with the ethical standards laid down in the 1964
Declaration of Helsinki.
RESULTS
All groups were compared with each another. IL-1b produc-
tion did not differ between the groups (Fig. 1).
The IFN- level was significantly lower in the HIV-1 pa-
tients group with secondary TB, with TB of more than five
years duration (HIV-1+TB), and in the HIV-1 without TB
group, compared with HIV-1/TB primary patients. The
level of IL-18 was significantly higher in HIV-1 patients
co-infected with TB, compared to the control group; IL-10
production was higher in the control group. In groups with
higher levels of IL-18, CD4 cell counts were lower. The
highest HIV-1 RNA viral load was observed in the HIV-1
group with primary TB infection and this group also had a
higher IFN- level. The lowest HIV-1 RNA viral loads were
observed in the control group. (Fig. 1)
T a b l e 1
CLINICAL AND DEMOGRAPHICAL INFORMATION ON PATIENTS





TB, n = 80
HIV-1 patients
with second-







Male 71 9 77 112
Female 9 3 15 62
Age, median
years
39 (25–60) 55 (43–65) 52 (41–64) 39 (30–65)
Fig.1. IL-1b levels (pg/ml) in patient groups.
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However, HIV-1/TB primary patients had significantly
higher IFN- and IL-18 production, and HIV-1 RNA viral
load, and lower IL-10 and CD4 cell counts. In addition, the
production of IL-18 was correlated with CD4 cell counts in
all groups. The highest levels of IFN- production and
HIV-1 RNA viral load were associated with significantly
lower CD4 cell counts (Fig. 2).
DISCUSSION
This study identified the interaction of IFN- with IL-10,
IL-18, IL-1b, and CD4 cell count and HIV-1 RNA viral
load in the development of HIV-1 in patients co-infected
with Mycobacterium tuberculosis. We measured the serum
levels of pro-inflammatory cytokines (IL-1b, IL-18, IFN-)
and anti-inflammatory cytokine (IL-10). The main findings
of this study were: 1) the serum IFN- level was signifi-
cantly higher in the HIV-1 patient group with primary TB,
2) patients with primary HIV-1/TB had higher IFN- levels
and HIV-1 RNA viral load, and lower IL-10 levels and CD4
cell counts, compared with the control group, 3) the level of
IL-18 was significantly higher in HIV-1 patients co-infected
with TB, 4) CD4 cell counts were lower in groups with
higher levels of IL-18, and 5) HIV-1/TB co-infection did
not seem to affect the median serum level of IL-1b in HIV-1
patients and there was no statistically significant difference
between TB positive and TB negative HIV-1 patients.
In individuals infected with HIV-1, the normal Th1 re-
sponse to viral infection is shifted to a Th2 response (Klein
et al., 1997; Osakwe et al., 2010). Measurement of the se-
rum cytokine levels of HIV-1 infected patients has shown
an increase in Th2 cytokine levels and a decrease in Th1 cy-
tokine levels. Our study showed that primary coinfection
with Mycobacterium tuberculosis shifts Th2 response to
Th1 (Klein et al., 1997; Osakwe et al., 2010).
In addition to the Th1 subset response mediation mentioned
earlier, IFN- normally acts on APCs to enhance their ex-
pression of major histocompatibility complex II (MHC-II),
thereby enhancing their antigen presentation ability (Li et
al., 2011). HIV-1 transactivator protein (TAT) interferes
with the intracellular signalling normally performed by the
IFN- bound IFN- receptor (Cheng et al., 2009). In so do-
ing, the TAT protein lowers the antigen presentation capac-
ity of dendritic cells and macrophages, further limiting the
immune response to the invading virus (Cheng et al., 2009;
Li et al., 2011).
IFN--producing CD4 T lymphocytes contribute to the gen-
eration of granulomas, besides being important co-stimula-
tors to the adequate activation of CD8 T lymphocytes. The
importance of CD4 T lymphocytes function is seen in pa-
tients with HIV, where the risk of TB increases with the de-
crease of cell counts (Spellberg and Edwards, 2001).
Clinical assessment of IFN- level in the serum of HIV-1+
TB in different clinical groups has been used to determine
the importance of IFN- in the pathogenesis of HIV-1 with
TB. The effects of IFN- are far-reaching, exhibiting poly-
functional effects on immune activation, proinflammatory
responses, and immune modulation. IFN- has a major ef-
fect on the regulation of antigen presentation by macro-
phages and dendritic cells, and in induction of class switch-
ing of B cells (Roff et al., 2013). As a proinflammatory
cytokine, IFN- directly activates phagocytic cells and stim-
ulates oxidative burst and the release of degradative en-
zymes, thereby supporting the host defence responses
against intracellular pathogens (Roff et al., 2013). Our study
revealed the presence of a high level of IFN- in HIV-1 pa-
tients with primary TB infection.
IFN- stimulates the production of reactive nitrogen inter-
mediates (RNIs), thus mediating the tuberculostatic func-
tion of macrophages, and also stimulates the migration of
immune cells to the infection site, contributing to
granuloma formation, which controls the disease progres-
sion. In chronic, stable disease, IFN- levels decline to a
steady state that is often equivalent to healthy controls
(Spellberg and Edwards, 2001; Roff et al., 2013). The pri-
mary TB infection in HIV-1 patients has induced IFN- pro-
duction that have reduced the adaptive immune responses to
the development of HIV-1. If not appropriately controlled,
such inflammatory activities can promote HIV-1 infection
Fig. 2. Cytokine levels, CD4 cell counts
and HIV-1RNA load in patient groups.
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and may cause a higher viral set point before T cell immu-
nity can control the HIV-1 load.
CONCLUSION
Our findings showed that IFN- in a group of patients with
HIV-1 and primary TB group had higher HIV-1 RNA viral
load and CD4 cell counts, as well as shifted Th2 response to
Th1. Increased IL-18 levels significantly lower CD4 cell
counts in HIV-1 patients co-infected with TB. Also, the ob-
served significantly higher levels of IFN- in the serum of
HIV-1 patients may reflect an active phase and latent M. tu-
berculosis infection, and may be a potential marker for im-
proving the targeting of preventative therapy to HIV-posi-
tive individuals with latent tuberculosis infection and in
HIV-positive individuals with high sensitivity TB.
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INTERFERONA-GAMMA (IFN-) LOMA IMÛNÂS ATBILDES REGULÇÐANÂ PACIENTIEM AR HIV-1 UN HIV-1 + MYCOBAC-
TERIUM TUBERCULOSIS
Raksta mçríis bija izpçtît IFN- lomu mijiedarbîbâ starp IL-10, IL-18, IL-1b un CD4 ðûnu skaitu un HIV-1 RNS vîrusu kopiju slodzes
skaitu HIV-1 infekcijas attîstîbâ pacientiem ar Mycobacterium tuberculosis (TB) dubultinfekciju. Pçtîjums veikts Rîgas Austrumu klîniskâs
universitâtes slimnîcas stacionârâ “Latvijas Infektoloìijas centrs” un Rîgas Stradiòa universitâtes Klîniskâs imunoloìijas un imunoìençtikas
starpkatedru laboratorijâ. Izanalizçti 200 ar HIV-1 inficçtie pacienti un 184 HIV-1 pacienti ar TB dubultinfekciju. IFN-, IL-10, IL-18,
IL-1b lîmeòi seruma paraugos noteikti, izmantojot ELISA tehnoloìijas bâzçto testçðanas sistçmu (ELISA Vector-best corporation,
Novosibirska, Krievija). CD4 ðûnu skaits noteikts, izmantojot plûsmas citometriju metodi (PARTEC IVD ASV), un HIV-1 vîrusa RNS
kopiju skaits plazmâ — izmantojot Cobas AmpliPrep /Cobas TaqMan HIV-1 Test (Vâcija). Mûsu iegûtie dati liecina, ka IFN- produkcija
bija bûtiski samazinâta, turpretî IL-10 produkcija un CD4 ðûnu skaits bija bûtiski palielinâjies HIV-1 pacientiem, salîdzinot ar HIV-1
pacientiem, kuri bija vienlaikus inficçti ar tuberkulozi. HIV-1 pacientiem, kuri bija vienlaikus inficçti ar tuberkulozi, bija bûtiski palielinâta
IL-18 produkcija. HIV-1 pacientiem, vienlaikus pirmreizçji inficçtiem ar tuberkulozi, IFN- produkcija un HIV-1 RNS vîrusu slodze bija
bûtiski palielinâta, bet IL-10 produkcija samazinâta, salîdzinot ar citam grupâm.
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